Adecuación de la seguridad del metamizol y agranulocitosis
Resumen: Objetivo: Analizar si la nota informativa de la Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), de 30 de octubre del 2018, sobre agranulocitosis y metamizol contiene la información precisa y necesaria para proteger a los pacientes de la aparición de esta reacción adversa (...
Main Authors: | Cristina Garcia del Campo, Miguel Murcia Soler, Inocencia Martinez-Mir, Vicente Palop Larrea |
---|---|
Format: | Article |
Language: | Spanish |
Published: |
Elsevier
2021-06-01
|
Series: | Atención Primaria |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0212656721000810 |
Similar Items
-
Metamizole-induced agranulocytosis (MIA): a mini review
by: Markos K. Tomidis Chatzimanouil, et al.
Published: (2023-08-01) -
Agranulocytosis after Metamizole Sodium Use
by: Eren Cagan, et al.
Published: (2015-09-01) -
Reactive Metamizole Metabolites Enhance the Toxicity of Hemin on the ATP Pool in HL60 Cells by Inhibition of Glycolysis
by: Deborah Rudin, et al.
Published: (2020-07-01) -
Metamizole: Current status of the safety and efficacy
by: Miljković Milijana N., et al.
Published: (2018-01-01) -
Leucopenia associated with metamizole: a case-control study
by: Swiss Medical Weekly
Published: (2017-05-01)